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In this issue ofCancerCell, two complementary papers byAtwood andcolleagues andSharpe and colleagues
show that basal cell carcinomas resistant to the Smoothened (SMO) inhibitor vismodegib frequently harbor
SMO mutations that limit drug binding, with mutations at some sites also increasing basal SMO activity.Basal cell carcinoma (BCC) of the skin is
the most common human cancer in lightly
pigmented individuals. Mutations acti-
vating the Hedgehog (HH) signaling
pathway drive BCC. Secreted HH exerts
its effects through binding to Patched
(PTCH), a 12-pass membrane bound re-
ceptor, which relieves PTCH inhibitory
activity on the downstream heptahelical
transmembrane protein Smoothened
(SMO). How PTCH actually inhibits SMO
is not clear, but SMO activation leads to
downstream activation of Gli transcription
factors that ultimately drive HH target
gene expression. Several human malig-
nancies including medulloblastoma (MB)
and BCC are driven by mutations in
one or more HH pathway genes, most
commonly PTCH1. Germline mutations
inPTCH1 causeGorlin’s syndrome, which
is associated with developmental abnor-
malities and tumor susceptibility that in-
cludes BCC and MB. HH signaling is
critical during embryologic development
but has only limited roles in adult tissues,
making it an excellent target for cancer
therapeutics.
The development of drugs targeting
the HH pathway began in 1957 when
Idaho farmers noted that many of their
newborn sheep were born with severe
developmental defects, including a single
cyclopic eye. Curiously, the pregnant
mothers had no obvious symptoms. An
11-year Food and Drug Administration
investigation eventually identified the
veratrum alkaloid cyclopamine, which
was present in the California corn lily
plant growing in the fields grazed by
sheep, as the causative agent. Thirty
years later, a pair of papers using avian
systems determined that cyclopamine
inhibits HH signaling, and the moleculartarget, Smoothened (SMO), was subse-
quently identified in 2000 (Cooper et al.,
1998; Incardona et al., 1998; Taipale
et al., 2000). That initial work defining
the SMO-cyclopamine interaction also
included the observation that some
SMO point mutants driving BCCs not
only increase basal SMO activity, but
simultaneously confer cyclopamine resis-
tance. The elegant and comprehensive
work presented by Atwood et al. (2015)
and Sharpe et al. (2015) in this issue of
Cancer Cell uses cutting edge technol-
ogy and a large collection of tumor
samples to pinpoint exact mutations in
SMO that confer resistance to vismode-
gib, the cyclopamine analog used to treat
HH driven tumors.
Because most BCCs are driven by
PTCH mutations, most tumors initially
respond to vismodegib. However, at least
20% develop resistance. The two papers
by Atwood et al. (2015) and Sharpe et al.
(2015) show that BCC resistance to the
SMO inhibitor is frequently the result of
mutations in SMO, similar to resistance
mechanisms for MB (Yauch et al., 2009).
Both groups sequenced DNA from
BCCs arising in three settings: (1) sponta-
neously in the general population, (2)
Gorlin’s syndrome patients, and (3) recur-
rent/resistant tumors in patients treated
with vismodegib. Findings from the two
studies are quite similar, showing that
15%–33% of untreated BCCs harbor
SMO mutations. This increases to 69%–
77% in resistant tumors. Resistant tumors
without SMO mutations still maintain HH
pathway activation, as evidenced by a
high level HH target gene (Gli) expression
and relatively unchanged tumor histology.
In many of these resistant cases without
SMO mutations, resistance is likely dueCancer Cellto mutations downstream of SMO at the
level of Gli2 or SUFU (a Gli regulator).
By aligning the mutations with a
recently solved crystal structure of the
SMO transmembrane domain, the au-
thors were able to separate the resis-
tance-associated mutations into two
groups: (1) mutations within or immedi-
ately adjacent to the ligand/drug binding
pocket and (2) mutations at more distant
sites. Using HH pathway reporter con-
structs in cell lines engineered to express
mutant SMO proteins, both groups
demonstrate that the resistance-associ-
ated mutations confer vismodegib resis-
tance. Interestingly, themutations outside
of the ligand binding pocket also increase
the basal activity of SMO, even in the
absence of the inhibitor. These mutations
include the W535L mutation, a bona fide
oncodriver highlighted in the seminal
work that established SMO as the cyclop-
amine target. Tumors harboring this mu-
tation at the outset should not respond
to vismodegib. In contrast, the binding
pocket mutations have little effect on
basal SMO activity and are likely not suffi-
cient oncodrivers on their own, because
most are still inhibited by PTCH1.
In addition to cell-based functional
studies demonstrating vismodegib resis-
tance and computer modeling predicting
altered binding affinity, Sharpe et al.
(2015) used physical biochemisty ap-
proaches with 3H-labeled vismodegib to
demonstrate that SMO mutations inside
and outside the ligand binding pocket
both compromise drug binding. They
also demonstrate that vismodegib resis-
tant mutations confer cross-resistance
to other small molecule SMO inhibitors,
suggesting that combinations of SMO in-
hibitors from the vismodegib class will27, March 9, 2015 ª2015 Elsevier Inc. 315
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Figure 1. HH Signaling Pathway
BCC is driven by activation of the HH pathway. Normally, Patched signaling in-
hibits Smoothened, which prevents Smoothened from activating Gli transcrip-
tion factors that transcribeHH target genes. Gli is also inhibited bySupressor of
fused (SUFU) and activated by aPKC-i/l. During development, and in a few
adult tissues, HH binds to Patched, releasing its inhibitory activity on SMO
and therebyactivating thepathway.BCC is drivenmost commonly by inactivat-
ing mutations in PTCH, although activating mutations in SMO or Gli can also
serve as oncodrivers. Tumor resistance to vismodegib usually results from
SMOmutations that prevent drug binding. Targeting the pathway downstream
may therefore be a useful therapeutic strategy. Red, elements that normally
suppressHHsignaling;green,elements that activate thepathway; yellow,phar-
macologic agents that may be useful for primary or vismodegib resistant BCC.
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therapeutic benefit.
As predicted by Peter
Nowell’s classic evolutionary
model of tumor development
(Nowell, 1976), the hetero-
geneity of mutations within
different cells within a tumor
protects against the demise
of the tumor by specifically
targeted therapies. The inevi-
table conclusion from this
work, as also seen with the
remarkable new therapies
for melanoma, is that, while
targeted agents can produce
spectacular initial responses,
resistance develops as minor
clones expand in the pres-
ence of drug. Both groups
conclude that, unlike many
other human malignancies,
which are capable of
engaging other mitogenic
pathways to circumvent tar-
geting inhibitors, BCC ap-
pears dependent on the
HHpathway. Therefore, over-
coming vismodegib resis-
tance will require combina-
tion therapy with agents thatinhibit SMO through different mecha-
nisms or that target the HH pathway at
points downstream of SMO. Potential
SMO-targeting agents with efficacy
against SMO resistant mutants include
substituted bis-amides (which have struc-
tural similarity to vismodegib) and the
FDA-approved antifungal agent itracona-
zole, which targets SMO at a site distinct
from vismodegib (Figure 1; Kim et al.,
2013). Perhaps the structural models of
the mutant SMO proteins presented in
these papers will inform the rational
design of a new generation of SMO inhib-
itors with improved resistance profiles.
However, activation of HH signaling316 Cancer Cell 27, March 9, 2015 ª2015 Elsdownstream of SMO would be predicted
to lead to resistance to any SMO-targeted
inhibitor, so an ideal therapeutic approach
may include a drug combination that also
targets Gli. In that regard, Atwood et al.
(2015) present data using an atypical pro-
tein kinase C i/l (aPKC-i/l) inhibitor that
inhibits Gli activation and retains efficacy
in the presence of the SMOmutations (At-
wood et al., 2015). This is an interesting
result with obvious therapeutic implica-
tions and is consistent with their previous
work showing that the aPKC-i/l inhibitor
is effective against cyclopamine-resistant
BCC cell lines (Atwood et al., 2013). Gli
protein can also be targeted with arsenicevier Inc.trioxide, which promotes Gli
protein degradation and also
inhibits HH activity driven by
an inhibitor-resistant SMO
mutation. Because BCC
tumors have demonstrated
several mechanisms of
bypassing SMO inhibitors
that maintain HH signaling,
perhaps the optimal thera-
peutic approach will be to
treat patients with multiple
inhibitors from the outset,
rather than sequentially as
resistant clones emerge.
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